Xilia-Trio 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The sustained-release (SR) formulation ensures prolonged therapeutic effects, promoting better patient compliance by reducing dosing frequency. Xilia-Trio 1 Tablet SR is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy. It should be used with caution in patients with renal or hepatic impairment, and periodic monitoring of blood glucose and renal function is recommended. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia, particularly due to Glimepiride. This combination therapy offers a comprehensive approach to managing type 2 diabetes by targeting multiple pathophysiological defects, thereby optimizing glycemic control and reducing the risk of diabetes-related complications.